| Literature DB >> 34885924 |
Manmath Narwane1, Dorothy Priyanka Dorairaj1,2, Yu-Lun Chang1, Ramasamy Karvembu2, Yu-Han Huang3, Hsueh-Wei Chang4,5, Sodio C N Hsu1,5.
Abstract
Zn(II) complexes bearing tris[3-(2-pyridyl)-pyrazolyl] borate (Tppy) ligand (1-3) was synthesized and examined by spectroscopic and analytical tools. Mononuclear [TppyZnCl] (1) has a Zn(II) centre with one arm (pyrazolyl-pyridyl) dangling outside the coordination sphere which is a novel finding in TppyZn(II) chemistry. In complex [TppyZn(H2O)][BF4] (2) hydrogen bonding interaction of aqua moiety stabilizes the dangling arm. In addition, solution state behaviour of complex 1 confirms the tridentate binding mode and reactivity studies show the exogenous axial substituents used to form the [TppyZnN3] (3). The complexes (1-3) were tested for their ability to bind with Calf thymus (CT) DNA and Bovine serum albumin (BSA) wherein they revealed to exhibit good binding constant values with both the biomolecules in the order of 104-105 M-1. The intercalative binding mode with CT DNA was confirmed from the UV-Visible absorption, viscosity, and ethidium bromide (EB) DNA displacement studies. Further, the complexes were tested for in vitro cytotoxic ability on four triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, MDA-MB-468, HCC1937, and Hs 578T). All three complexes (1-3) exhibited good IC50 values (6.81 to 16.87 μM for 24 h as seen from the MTS assay) results which indicated that these complexes were found to be potential anticancer agents against the TNBC cells.Entities:
Keywords: biomolecular interactions; in vitro cytotoxicity; triple negative breast cancer cells; tris(pyrazolyl)borates; zinc(II)
Mesh:
Substances:
Year: 2021 PMID: 34885924 PMCID: PMC8659194 DOI: 10.3390/molecules26237341
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Synthesis of mononuclear TppyZn(II) complexes.
Figure 1Molecular structure of (a) [TppyZnCl] (1), (b) [TppyZn(OH2)](BF4) (2) and (c) [TppyZn(N3)] (3), showing 50% ellipsoid probability and partial atom numbering schemes. All hydrogen atoms were omitted for clarity except those of water molecule in complex 2.
Scheme 2Temperature dependent interconversion of binding mode transformation of 1.
Figure 2(a) Absorption spectra of complex 1 in Tris-HCl buffer upon addition of CT DNA. [complex] = 2.0 × 10−5 M, [DNA] = 0–45 µM. The arrow shows that the absorption intensity decreases upon increasing the CT DNA concentration. (b) Plot of [DNA]/(εa − εf) versus [DNA] for the titration of the complexes with CT DNA. (c) Absorption spectra of the Tppy ligand in Tris-HCl buffer upon addition of CT DNA. [complex] = 2.5 × 10−5 M, [DNA] = 0–45 µM.
Figure 3(a) Fluorescence quenching curves of EB bound to DNA in the presence of complex 1. [DNA] = 5 µM, [EB] = 5 µM, and [complex] = 0–50 µM. (b) Stern–Volmer plot of fluorescence titrations of the complexes with CT DNA.
Figure 4(a) a Fluorescence quenching curves of BSA in the absence and presence of 1. [BSA] = 1 µM and [complex] = 0–20 µM (b) Stern–Volmer plot for the fluorescence titrations of complexes 1–3 with BSA.
Figure 5Scatchard plot for the fluorescence titrations of complexes 1–3 with BSA.
Figure 6(a) Molecular docked pose of 1 with DNA. (b) Zoomed image of the molecular docked pose of 1 with DNA.
IC50 (µM) values of the Zn(II) complexes 1–3 against TNBC cell lines after 24 h incubation. Data, mean ± SD (n = 3).
| Cancer Cell Lines | 1 | 2 |
|---|---|---|
| MDA-MB-231 | 6.81 | 8.85 |
| MDA-MB-468 | 16.56 | 10.85 |
| HCC1937 | 13.54 | 10.60 |
| Hs578T | 12.51 | 6.68 |